Michael Barbella, Managing Editor06.01.24
Money matters mattered most this post-holiday week on the MPO website.
Nordson Corporation and Surmodics boosted pageviews with M&A-related news, while CamDiab drove traffic with a regulatory update. Vyaire Medical, meanwhile, gained unwanted attention for its Class I recall troubles.
Nordson topped traffic totals by announcing an $800 million deal to acquire Atrion Corporation, a company specializing in medical infusion fluid delivery and niche cardiovascular solutions. Allen, Texas-based Atrion generated about $169 million in annual revenue in 2023; its portfolio consists of three businesses: Halkey Roberts, Atrion Medical, and Quest Medical. The company was established in 1944 and has three specialized FDA-registered U.S. manufacturing facilities.
A pending private equity purchase boosted Surmodics' profile: The Eden Prairie, Minn.-based company is being acquired by GTCR, a PE firm with investment expertise in healthcare and healthcare technology, for $627 million. The $43 per-share acquisition price is a 41.1% premium to Surmodics’ 30-day trading day volume-weighted average closing price through May 28. Surmodics’ board unanimously approved the deal and the transaction is anticipated to close in the next six months.
CamDiab proved to be a significant site visitor lure, thanks to the FDA authorization of its CamAPS FX adaptive, hybrid closed-loop app as an interoperable glycemic controller device. The Android app helps manage glucose levels in patients with type 1 diabetes age two and older, including during pregnancy. The CamAPS FX app lets a compatible insulin pump and continuous glucose monitor “speak” to each other and create an “artificial pancreas.” The closed-loop algorithm—extensively tested in clinical trials—is CE marked for use in the U.K. and Europe.
Vyaire Medical's pageview piling proficiency came at the cost of a Class I recall. The company is recalling its Twin Tube in the Vyntus CPX system over its nozzle-separation potential. The separated component may fall into the patient’s mouth, causing a potential choking hazard. The recall affects devices distributed from Jan. 1, 2015, to June 30, 2023. The company has not yet received reports of injury or deaths related to the issue.
Nordson Corporation and Surmodics boosted pageviews with M&A-related news, while CamDiab drove traffic with a regulatory update. Vyaire Medical, meanwhile, gained unwanted attention for its Class I recall troubles.
Nordson topped traffic totals by announcing an $800 million deal to acquire Atrion Corporation, a company specializing in medical infusion fluid delivery and niche cardiovascular solutions. Allen, Texas-based Atrion generated about $169 million in annual revenue in 2023; its portfolio consists of three businesses: Halkey Roberts, Atrion Medical, and Quest Medical. The company was established in 1944 and has three specialized FDA-registered U.S. manufacturing facilities.
A pending private equity purchase boosted Surmodics' profile: The Eden Prairie, Minn.-based company is being acquired by GTCR, a PE firm with investment expertise in healthcare and healthcare technology, for $627 million. The $43 per-share acquisition price is a 41.1% premium to Surmodics’ 30-day trading day volume-weighted average closing price through May 28. Surmodics’ board unanimously approved the deal and the transaction is anticipated to close in the next six months.
CamDiab proved to be a significant site visitor lure, thanks to the FDA authorization of its CamAPS FX adaptive, hybrid closed-loop app as an interoperable glycemic controller device. The Android app helps manage glucose levels in patients with type 1 diabetes age two and older, including during pregnancy. The CamAPS FX app lets a compatible insulin pump and continuous glucose monitor “speak” to each other and create an “artificial pancreas.” The closed-loop algorithm—extensively tested in clinical trials—is CE marked for use in the U.K. and Europe.
Vyaire Medical's pageview piling proficiency came at the cost of a Class I recall. The company is recalling its Twin Tube in the Vyntus CPX system over its nozzle-separation potential. The separated component may fall into the patient’s mouth, causing a potential choking hazard. The recall affects devices distributed from Jan. 1, 2015, to June 30, 2023. The company has not yet received reports of injury or deaths related to the issue.